Clinical trials: Multiple Myeloma
Multiple Myeloma, Lymphomas
Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.
The main aim of the study was to evaluate the clinical impact of different DMSO concentrations in cryopreservation mixture (5%, 7.5%, 10%) on reconstitution of hematopoiesis after autologous hematopoietic stem cell…
- Conditions
- Multiple Myeloma, Lymphomas, Leukemias
- Trial name
- DMSOconc3 (NCT02452099)
- Testing
- Cryopreservation of HSCs using 5% DMSO concentration, Cryopreservation of HSCs using 7,5% DMSO concentration, Cryopreservation of HSCs using 10% DMSO concentration
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Trial name
- NCT00014508
- Testing
- sargramostim, cyclophosphamide, cyclosporine
- Where
- 12 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
This is a multi-center, phase I/II clinical trial for patients who have relapsed more than 60 day after allogeneic transplant for a hematologic malignancy. The study consists of two phases.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Lymphoma
- Trial name
- NCT01885897
- Testing
- ALT-803
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients
This is a randomized controlled pilot study designed to evaluate whether the beta-adrenergic antagonist propranolol is effective in decreasing gene expression of stress-mediated beta-adrenergic pathways among a cohort of…
- Trial name
- NCT02420223
- Testing
- Propranolol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Medical College of Wisconsin
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients.
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Trial name
- NCT00901225
- Testing
- G-CSF plus Plerixafor
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Myeloma
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma…
- Trial name
- NCT04680468
- Testing
- Belantamab mafodotin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma
Study of XL999 in Patients With Multiple Myeloma
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00304590
- Testing
- XL999
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Symphony Evolution, Inc.
Relapsed or Refractory Multiple Myeloma
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
The purpose of this study is to evaluate the clinical activity of vorinostat in combination with bortezomib in participants with relapsed or refractory multiple myeloma after at least 2 prior treatment regimens.
- Trial name
- NCT00773838
- Testing
- Vorinostat, Bortezomib, Dexamethasone
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma, Non-Hodgkin Lymphoma
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia
- Trial name
- NCT01343368
- Testing
- Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)
This study is a Phase Ib open label, single arm, adaptive multicentre trial. Patients with newly diagnosed Multiple Myeloma (MM) will be treated with Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) in combination with…
- Trial name
- CyBorD-Dara (NCT02955810)
- Testing
- Daratumumab, Cyclophosphamide, Bortezomib
- Where
- Ireland
- Volunteers
- 18 people
- Sponsor
- National University of Ireland, Galway, Ireland
Hematologic Malignancies
Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
Primary: Define the maximal tolerated dose (MTD) of VNP40401M when given with hematopoietic cell transplantation (HCT) Secondary: Describe the change in pharmacokinetic (PK) parameters with increasing doses of drug.
- Trial name
- NCT00521859
- Testing
- Cloretazine, Fludarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma and Malignant Plasma Cell Neoplasms
Multiple Myeloma t(4 ;14) FFPE Samples
This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with 4;14 translocated multiple myeloma, together with their…
- Trial name
- MM-t4-14-FFPE (NCT07482761)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- BIWAKO
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00008242
- Testing
- dexamethasone, doxorubicin hydrochloride, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
The purpose of this study is to determine the efficacy of Ixazomib when combined with Pomalidomide and Dexamethasone, in terms of overall response rate in subjects with relapsed Multiple Myeloma
- Trial name
- NCT02578121
- Testing
- Ixazomib, Pomalidomide, Dexamethasone
- Where
- United States
- Sponsor
- University of Arkansas
AL Amyloidosis, Multiple Myeloma
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
This study evaluates whether daily SMS-based (text messages) symptom monitoring is feasible and acceptable in patients who are undergoing treatment for multiple myeloma (MM) or systemic light chain amyloidosis (AL), and whether…
- Trial name
- NCT07850284
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Mayo Clinic
Relapsed/Refractory Multiple Myeloma
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among…
- Trial name
- NCT06369935
- Testing
- Equecabtagene Autoleucel
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Peking University People's Hospital
Multiple Myeloma
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma
A total of 40 Multiple Myeloma (MM) patients at clinical relapse who progressed during Proteasome Inhibitors (PIs) or Immunomodulating Drugs (IMiDs)-based therapies and who are assigned to antiCD38-based salvage treatments, will…
- Trial name
- NCT03848676
- Testing
- Evaluation of patients resistance to immunotherapies in Multiple Myeloma
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Turin, Italy
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer.
- Trial name
- NCT00028886
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 17 sites in Belgium, Netherlands
- Volunteers
- 450 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek